BD Biosciences
BD Biosciences

Pharma Learns from Carmakers

Some Big Pharma companies are turning to the world’s automobile makers for advice on innovation and profitability.

By | December 14, 2011

Assembly line at Hyundai Motor Company’s car factory in Ulsan, South Korea WIKIMEDIA COMMONS, TANELI RAJALA

In the past couple of years, big time drugmakers, including GlaxoSmithKline and AstraZeneca, have begun to turn to an unusual advisor for support: automobile manufacturers. While the products of the two industries may have little in common, the structures of the companies are becoming more and more similar.

In 2009, AstraZeneca looked to Jaguar Land Rover, part of India's Tata Motors, for manufacturing advice, Reuters reported. And just a few months ago, GlaxoSmithKline teamed up with McLaren’s Formula One engineers for input on innovation and overall process procedures.

The trend may stem from the rising pressures on the pharmaceutical industry, as patents for big name brand drugs expire and the regulatory landscape makes it increasingly difficult for new drugs to enter the market. "The good old days of the pharmaceutical industry are gone forever," according to a report issued by management consulting firm McKinsey last week.

The situation parallels that of the automobile industry not too long ago, which is precisely why pharma companies are coming here for advice. The depressed economy forced car manufacturers to streamline the process and cut significant costs by outsourcing and down-sizing. While carmakers once did much of the work in-house, they now take on a more administrative role, coordinating contractors and suppliers who do the bulk of the work. As a result, the average product development time in the industry has fallen by nearly 30 percent, according to Porsche. In pharma, on the other hand, the average product development time has risen by 30 percent.

"In terms of production costs, the auto industry may be a model for other industries,” Reto Hess, who coordinates analysis of global car makers at Credit Suisse Private Banking, told Reuters. “The amount of high tech that is offered at affordable prices in today's cars is remarkable." For pharma, this could mean outsourcing more and more of the work to CROs and licensed biotech companies, as research budgets continue to dwindle.


Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo
EMD Millipore
EMD Millipore

Popular Now

  1. The Mycobiome
    Features The Mycobiome

    The largely overlooked resident fungal community plays a critical role in human health and disease.

  2. Simulating Scientific Sabotage, For Fun
  3. Antibody Alternatives
    Features Antibody Alternatives

    Nucleic acid aptamers and protein scaffolds could change the way researchers study biological processes and treat disease.

  4. Holding Their Ground
    Features Holding Their Ground

    To protect the global food supply, scientists want to understand—and enhance—plants’ natural resistance to pathogens.

Life Technologies